Resultados a largo plazo de una cohorte chilena: la edad del paciente no incide en el resultado del trasplante alogénico de precursores hematopoyéticos para leucemia mieloide aguda

Background: In our country, transplantation centers differ in the age limit for allogeneic hematopoietic transplantation (ALOHT). In our program, transplants with age- adjusted conditioning are performed in patients until 70 years old. Currently more than 60% of ALOHT reported to the Center for Int...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sarmiento,Mauricio, Rojas,Patricio, Triantafilo,Nicolás, Campbell,James, García,María José, Ocqueteau,Mauricio, Sandoval,Vicente, Rojas,Andrés, Gazmuri,José Tomás, Guerrero,Gonzalo, Vergara,Maximiliano, Bertin,Pablo, Ramírez,Pablo, Jara,Verónica, Gutiérrez,Catherine, Soto,Katherine, Arellano,Silvana, Pizarro,Isabel, Lorca,Carla, Rivera,Elizabeth, Álvarez,Elvira, Valdés,Marcia, Pereira,Jaime, Barriga,Francisco
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2021
Materias:	Leukemia Survival Transplantation, Homologous
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872021000100022
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872021000100022
record_format	dspace
spelling	oai:scielo:S0034-988720210001000222021-05-09Resultados a largo plazo de una cohorte chilena: la edad del paciente no incide en el resultado del trasplante alogénico de precursores hematopoyéticos para leucemia mieloide agudaSarmiento,MauricioRojas,PatricioTriantafilo,NicolásCampbell,JamesGarcía,María JoséOcqueteau,MauricioSandoval,VicenteRojas,AndrésGazmuri,José TomásGuerrero,GonzaloVergara,MaximilianoBertin,PabloRamírez,PabloJara,VerónicaGutiérrez,CatherineSoto,KatherineArellano,SilvanaPizarro,IsabelLorca,CarlaRivera,ElizabethÁlvarez,ElviraValdés,MarciaPereira,JaimeBarriga,Francisco Leukemia Survival Transplantation, Homologous Background: In our country, transplantation centers differ in the age limit for allogeneic hematopoietic transplantation (ALOHT). In our program, transplants with age- adjusted conditioning are performed in patients until 70 years old. Currently more than 60% of ALOHT reported to the Center for International Bone Marrow Transplantation Research (CIBMTR) are performed in patients older than 40 years. Aim: To report our experience with ALOHT in acute myelogenous leukemia (AML), analyzing patient age at transplantation in different periods and transplant results in different age groups. Material and Methods: A retrospective analysis of the database of adult hematopoietic transplants in AML patients was performed. Demographic data, disease characteristics, transplant data, survival and relapse times, and mortality were collected. Results: In our program, 1030 transplants were performed in adults and 119 ALOHT were performed in AML patients, between 1990 and 2020. The median age of patients in all periods was 41 years, (range 16-69). The median age was 33 and 45 years, in the periods 1990-2000 and 2000-2020 respectively (p < 0.01). Seventy-eight patients received myeloablative conditioning (median age 44 years) and 41 reduced intensity conditioning (median age 53 years). Five-year overall survival was 44.6% (confidence intervals (CI) 41-48). Non relapse mortality of all periods was 19% (CI 17 - 40%) and relapse rate was 17 % (CI 16-22). No difference in five years overall survival among patients younger than 40, 41 to 50 and over 51 years was observed. Conclusions: Overall Survival, non-relapse mortality and relapse rate were similar in younger and older patients in our program and similar to those previously reported in other centers.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.149 n.1 20212021-01-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872021000100022es10.4067/S0034-98872021000100022
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Leukemia Survival Transplantation, Homologous
spellingShingle	Leukemia Survival Transplantation, Homologous Sarmiento,Mauricio Rojas,Patricio Triantafilo,Nicolás Campbell,James García,María José Ocqueteau,Mauricio Sandoval,Vicente Rojas,Andrés Gazmuri,José Tomás Guerrero,Gonzalo Vergara,Maximiliano Bertin,Pablo Ramírez,Pablo Jara,Verónica Gutiérrez,Catherine Soto,Katherine Arellano,Silvana Pizarro,Isabel Lorca,Carla Rivera,Elizabeth Álvarez,Elvira Valdés,Marcia Pereira,Jaime Barriga,Francisco Resultados a largo plazo de una cohorte chilena: la edad del paciente no incide en el resultado del trasplante alogénico de precursores hematopoyéticos para leucemia mieloide aguda
description	Background: In our country, transplantation centers differ in the age limit for allogeneic hematopoietic transplantation (ALOHT). In our program, transplants with age- adjusted conditioning are performed in patients until 70 years old. Currently more than 60% of ALOHT reported to the Center for International Bone Marrow Transplantation Research (CIBMTR) are performed in patients older than 40 years. Aim: To report our experience with ALOHT in acute myelogenous leukemia (AML), analyzing patient age at transplantation in different periods and transplant results in different age groups. Material and Methods: A retrospective analysis of the database of adult hematopoietic transplants in AML patients was performed. Demographic data, disease characteristics, transplant data, survival and relapse times, and mortality were collected. Results: In our program, 1030 transplants were performed in adults and 119 ALOHT were performed in AML patients, between 1990 and 2020. The median age of patients in all periods was 41 years, (range 16-69). The median age was 33 and 45 years, in the periods 1990-2000 and 2000-2020 respectively (p < 0.01). Seventy-eight patients received myeloablative conditioning (median age 44 years) and 41 reduced intensity conditioning (median age 53 years). Five-year overall survival was 44.6% (confidence intervals (CI) 41-48). Non relapse mortality of all periods was 19% (CI 17 - 40%) and relapse rate was 17 % (CI 16-22). No difference in five years overall survival among patients younger than 40, 41 to 50 and over 51 years was observed. Conclusions: Overall Survival, non-relapse mortality and relapse rate were similar in younger and older patients in our program and similar to those previously reported in other centers.
author	Sarmiento,Mauricio Rojas,Patricio Triantafilo,Nicolás Campbell,James García,María José Ocqueteau,Mauricio Sandoval,Vicente Rojas,Andrés Gazmuri,José Tomás Guerrero,Gonzalo Vergara,Maximiliano Bertin,Pablo Ramírez,Pablo Jara,Verónica Gutiérrez,Catherine Soto,Katherine Arellano,Silvana Pizarro,Isabel Lorca,Carla Rivera,Elizabeth Álvarez,Elvira Valdés,Marcia Pereira,Jaime Barriga,Francisco
author_facet	Sarmiento,Mauricio Rojas,Patricio Triantafilo,Nicolás Campbell,James García,María José Ocqueteau,Mauricio Sandoval,Vicente Rojas,Andrés Gazmuri,José Tomás Guerrero,Gonzalo Vergara,Maximiliano Bertin,Pablo Ramírez,Pablo Jara,Verónica Gutiérrez,Catherine Soto,Katherine Arellano,Silvana Pizarro,Isabel Lorca,Carla Rivera,Elizabeth Álvarez,Elvira Valdés,Marcia Pereira,Jaime Barriga,Francisco
author_sort	Sarmiento,Mauricio
title	Resultados a largo plazo de una cohorte chilena: la edad del paciente no incide en el resultado del trasplante alogénico de precursores hematopoyéticos para leucemia mieloide aguda
title_short	Resultados a largo plazo de una cohorte chilena: la edad del paciente no incide en el resultado del trasplante alogénico de precursores hematopoyéticos para leucemia mieloide aguda
title_full	Resultados a largo plazo de una cohorte chilena: la edad del paciente no incide en el resultado del trasplante alogénico de precursores hematopoyéticos para leucemia mieloide aguda
title_fullStr	Resultados a largo plazo de una cohorte chilena: la edad del paciente no incide en el resultado del trasplante alogénico de precursores hematopoyéticos para leucemia mieloide aguda
title_full_unstemmed	Resultados a largo plazo de una cohorte chilena: la edad del paciente no incide en el resultado del trasplante alogénico de precursores hematopoyéticos para leucemia mieloide aguda
title_sort	resultados a largo plazo de una cohorte chilena: la edad del paciente no incide en el resultado del trasplante alogénico de precursores hematopoyéticos para leucemia mieloide aguda
publisher	Sociedad Médica de Santiago
publishDate	2021
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872021000100022
work_keys_str_mv	AT sarmientomauricio resultadosalargoplazodeunacohortechilenalaedaddelpacientenoincideenelresultadodeltrasplantealogenicodeprecursoreshematopoyeticosparaleucemiamieloideaguda AT rojaspatricio resultadosalargoplazodeunacohortechilenalaedaddelpacientenoincideenelresultadodeltrasplantealogenicodeprecursoreshematopoyeticosparaleucemiamieloideaguda AT triantafilonicolas resultadosalargoplazodeunacohortechilenalaedaddelpacientenoincideenelresultadodeltrasplantealogenicodeprecursoreshematopoyeticosparaleucemiamieloideaguda AT campbelljames resultadosalargoplazodeunacohortechilenalaedaddelpacientenoincideenelresultadodeltrasplantealogenicodeprecursoreshematopoyeticosparaleucemiamieloideaguda AT garciamariajose resultadosalargoplazodeunacohortechilenalaedaddelpacientenoincideenelresultadodeltrasplantealogenicodeprecursoreshematopoyeticosparaleucemiamieloideaguda AT ocqueteaumauricio resultadosalargoplazodeunacohortechilenalaedaddelpacientenoincideenelresultadodeltrasplantealogenicodeprecursoreshematopoyeticosparaleucemiamieloideaguda AT sandovalvicente resultadosalargoplazodeunacohortechilenalaedaddelpacientenoincideenelresultadodeltrasplantealogenicodeprecursoreshematopoyeticosparaleucemiamieloideaguda AT rojasandres resultadosalargoplazodeunacohortechilenalaedaddelpacientenoincideenelresultadodeltrasplantealogenicodeprecursoreshematopoyeticosparaleucemiamieloideaguda AT gazmurijosetomas resultadosalargoplazodeunacohortechilenalaedaddelpacientenoincideenelresultadodeltrasplantealogenicodeprecursoreshematopoyeticosparaleucemiamieloideaguda AT guerrerogonzalo resultadosalargoplazodeunacohortechilenalaedaddelpacientenoincideenelresultadodeltrasplantealogenicodeprecursoreshematopoyeticosparaleucemiamieloideaguda AT vergaramaximiliano resultadosalargoplazodeunacohortechilenalaedaddelpacientenoincideenelresultadodeltrasplantealogenicodeprecursoreshematopoyeticosparaleucemiamieloideaguda AT bertinpablo resultadosalargoplazodeunacohortechilenalaedaddelpacientenoincideenelresultadodeltrasplantealogenicodeprecursoreshematopoyeticosparaleucemiamieloideaguda AT ramirezpablo resultadosalargoplazodeunacohortechilenalaedaddelpacientenoincideenelresultadodeltrasplantealogenicodeprecursoreshematopoyeticosparaleucemiamieloideaguda AT jaraveronica resultadosalargoplazodeunacohortechilenalaedaddelpacientenoincideenelresultadodeltrasplantealogenicodeprecursoreshematopoyeticosparaleucemiamieloideaguda AT gutierrezcatherine resultadosalargoplazodeunacohortechilenalaedaddelpacientenoincideenelresultadodeltrasplantealogenicodeprecursoreshematopoyeticosparaleucemiamieloideaguda AT sotokatherine resultadosalargoplazodeunacohortechilenalaedaddelpacientenoincideenelresultadodeltrasplantealogenicodeprecursoreshematopoyeticosparaleucemiamieloideaguda AT arellanosilvana resultadosalargoplazodeunacohortechilenalaedaddelpacientenoincideenelresultadodeltrasplantealogenicodeprecursoreshematopoyeticosparaleucemiamieloideaguda AT pizarroisabel resultadosalargoplazodeunacohortechilenalaedaddelpacientenoincideenelresultadodeltrasplantealogenicodeprecursoreshematopoyeticosparaleucemiamieloideaguda AT lorcacarla resultadosalargoplazodeunacohortechilenalaedaddelpacientenoincideenelresultadodeltrasplantealogenicodeprecursoreshematopoyeticosparaleucemiamieloideaguda AT riveraelizabeth resultadosalargoplazodeunacohortechilenalaedaddelpacientenoincideenelresultadodeltrasplantealogenicodeprecursoreshematopoyeticosparaleucemiamieloideaguda AT alvarezelvira resultadosalargoplazodeunacohortechilenalaedaddelpacientenoincideenelresultadodeltrasplantealogenicodeprecursoreshematopoyeticosparaleucemiamieloideaguda AT valdesmarcia resultadosalargoplazodeunacohortechilenalaedaddelpacientenoincideenelresultadodeltrasplantealogenicodeprecursoreshematopoyeticosparaleucemiamieloideaguda AT pereirajaime resultadosalargoplazodeunacohortechilenalaedaddelpacientenoincideenelresultadodeltrasplantealogenicodeprecursoreshematopoyeticosparaleucemiamieloideaguda AT barrigafrancisco resultadosalargoplazodeunacohortechilenalaedaddelpacientenoincideenelresultadodeltrasplantealogenicodeprecursoreshematopoyeticosparaleucemiamieloideaguda
_version_	1718437176699518976

Resultados a largo plazo de una cohorte chilena: la edad del paciente no incide en el resultado del trasplante alogénico de precursores hematopoyéticos para leucemia mieloide aguda

Ejemplares similares